All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit Know GvHD.

The GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The GvHD Hub

Brought to you by Scientific Education Support

Scientific Education Support

The GVHD Hub is an independent medical education platform, sponsored by Medac and supported through independent educational grants from Incyte, Sanofi and Therakos. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

My GvHD Hub

Create an account to access:

Bookmark & personalize site content

Receive alerts for new content in your areas of interest

View GvHD content recommended for you

EBMT 2022

Share:

Mar 31, 2022

X post image

23 Nov 2022

Have you seen this?
#EBMT22 | 🎧 The GvHD Hub was pleased to speak to @zina_peric and @BipinSavani. We asked, What should supportive care look like for patients with #GvHD? What role does physical activity play in these patients?
https://t.co/Ok2M00mK9A

X post image

16 Nov 2022

Have you listened to this?
#EBMT22 | 🎧 The GvHD Hub was pleased to speak to Daniel Weisdorf, University of Minnesota. We asked, How do we stratify risk in patients with #GvHD?
Listen to the 3 min podcast here 👇
https://t.co/5C5opujj1f

X post image

3 Nov 2022

Have you watched this yet?
#EBMT22 | 🎥 The ALL Hub spoke with Giovanna Lucchini, @GreatOrmondSt. We asked, How does #GvHD affect outcomes for pediatric patients undergoing allo-SCT for ALL?

https://t.co/YANFNE2DiG

X post image

19 Oct 2022

Catch up with this!
🎥 #EBMT22 | The GvHD Hub was pleased to speak to Mohamad Mohty, Hôpital Saint-Antoine, Paris, FR. We asked, When would you use ATG vs PTCy for GvHD prophylaxis?

👉 https://t.co/6g5ifFU3a5

#GvHD #GvHDsm

X post image

1 Aug 2022

🎧 Re-listen to this podcast from #EBMT22 👀
The GvHD Hub was pleased to speak to Daniel Weisdorf, University of Minnesota. We asked, How do we stratify risk in patients with #GvHD❓
Listen to the 3 min podcast here 👇
https://t.co/5C5opuAUpP

X post image

14 May 2022

When would you use ATG vs PTCy for #GvHD prophylaxis❓ Check out this clip from @Mohty_EBMT, and watch the full video on the GvHD Hub website 👇 #EBMT22

👉 https://t.co/6g5ifFTvkx 👈

X post image

14 Apr 2022

#EBMT22 🎧The GvHD Hub was pleased to speak to @zina_peric, University of Zagreb, and @BipinSavani, Vanderbilt University Medical Center. We asked, What should supportive care look like for patients with #GvHD? What role does physical activity play?

👉 https://t.co/Ok2M00mck2 👈

X post image

11 Apr 2022

🎧 During #EBMT22, the GvHD Hub was pleased to speak to Daniel Weisdorf, @UMNews. We asked, How do we stratify risk in patients with #GvHD❓
Listen to the 3 min podcast here 👇

👉 https://t.co/5C5opuBsfn 👈

X post image

7 Apr 2022

🎥 During #EBMT22, the ALL Hub spoke with Giovanna Lucchini, @GreatOrmondSt. We asked, How does #GvHD affect outcomes for pediatric patients undergoing allo-SCT for ALL❓

👉 https://t.co/YANFNE2DiG 👈

X post image

29 Mar 2022

Visit our Twitter moment for a summary of hot GvHD topics presented at #EBMT22 https://t.co/966l87Itea

X post image

24 Mar 2022

🎥 #EBMT22 | The GvHD Hub was pleased to speak to Mohamad Mohty, Hôpital Saint-Antoine, Paris, FR. We asked, When would you use ATG vs PTCy for GvHD prophylaxis❓

👉 https://t.co/6g5ifGb6c5 👈

#GvHD #GvHDsm

X post image

23 Mar 2022

That’s the end of our coverage for the EBMT 48th Annual Meeting!

We hope you’ve enjoyed following EBMT live congress updates with us, from key points, interviews and more.

Keep an eye out for post-congress coverage of EBMT highlights and important topics.

#EBMT22

X post image

23 Mar 2022

Congress #EBMT22| Francesca Biavasco, @Uniklinik_Fr, presents a poster on the real world data from a retrospective analysis of that confirms the response rate to ruxolitinib as a second-line therapy in SR-GI-GvHD obtained in REACH2 trial and the poor outcome of SR-GI-GVHD. #gvhd

X post image

23 Mar 2022

CONGRESS #EBMT22 | Friedrich Stölzel presents a subgroup analysis of MC-FludT.14/L. FT10 conditioning favoured over FB2 before allo-SCT in AML wrt incidence of extensive cGvHD & GRFS. No difference wrt EFS, OS, relapse or NRM. #bmtsm #gvhdsm #leusm

X post image

23 Mar 2022

Congress #EBMT22| Daniel Lysak, @FNPlzen, discusses mesenchymal stem cells as a treatment of #GVHD. #bmtsm

X post image

23 Mar 2022

Congress #EBMT22| @seckinerdal, @AcibademSaglik, discusses supportive care for patients with severe acute #GvHD. We highlight the skin symptom management. #bmtsm

X post image

23 Mar 2022

CONGRESS #EBMT22 | @RShouval @MSKCancerCenter presents a workshop session on fecal microbiota transplantation for acute #GvHD. #bmtsm #gvhdsm

X post image

23 Mar 2022

Congress #EBMT22| @mesireaydin, @amsterdamumc, discusses results of a study investigating ATG- vs PTCy-based conditioning regimens on #GvHD incidence, concluding PTCy is associated with a lower incidence of aGvHD grade II-IV compared to ATG (46% vs 23%, p= 0.0009). #bmtsm

X post image

23 Mar 2022

Congress #EBMT22| @KordelasLambros, @UniklinikEssen, discussed a prospective study investigating the clinical significance of soluble PD-1 after alloHSCT on #GvHD, relapse, and overall survival (OS). He concludes it may predict moderate or severe cGvHD & inferior OS. #bmtsm

X post image

23 Mar 2022

Congress #EBMT22| Mario Delia, @polibari2020, presents data from a prosepective, multicenter study that seems to confirm the value of graft T-regulatory cells in preventing acute #GvHD (HR, 0.25) but favouring chronic GvHD (HR, 2.99). #bmtsm

X post image

23 Mar 2022

Congress #EBMT22| @ProfLocatelli, @bambinogesu, discusses biomarker analysis of the phase III REACH3 study for SR-cGvHD, concluding that baseline inflammatory biomarker, chemokine, and immune cell levels did not predict response to ruxolitinib. #gvhd #bmtsm

X post image

23 Mar 2022

CONGRESS #EBMT22 | Lev Gorfinkel @DanaFarber presents a secondary analysis of ABA2: overlap cGvHD is associated with worse 2-yr NRM, DFS & OS than classic disease; abtacept treatment may be protective #bmtsm #gvhdsm

X post image

23 Mar 2022

CONGRESS #EBMT22 | Maria Teresa Lupo-Stanghellini @SanRaffaeleMI confirmed efficacy of the Minnesota Risk Score to stratify aGvHD patients for both TRM and OS probability in the setting of PTCy. Standard-risk pts had significantly better D28 ORR than high-risk pts #bmtsm #gvhdsm

X post image

23 Mar 2022

CONGRESS #EBMT22 | Phase I/II iMAGINE study of ibrutinib in pediatric cGvHD presented by Marco Zecca: grade ≥3 TEAE 64%, ORR 78% (83% 1L; 77% R/R) #bmtsm #gvhdsm

X post image

23 Mar 2022

CONGRESS #EBMT22 | Updated EQUATE trial results of itolizumab in aGvHD presented by @DrCCutler @DanaFarber: D29 CR 52%, ORR 64%. #bmtsm #gvhdsm

X post image

23 Mar 2022

CONGRESS #EBMT22 | REACH2 trial results: acute #GvHD response to ruxolitinib by organ involvement presented by @mohty_EBMT. Improvement in Day 28 ORR and aGvHD grade for all organ classes vs BAT. #bmtsm #gvhdsm

X post image

23 Mar 2022

CONGRESS #EBMT22 | Steve Connelly presents EQUATE phase 1b/2 trial interim data: itolizumab causes dose-dependent decrease in T-cell surface CD6, reduction in effector T cells and is associated with response in patients with acute #GvHD. #bmtsm #gvhdsm

X post image

23 Mar 2022

CONGRESS #EBMT22 | Erik Thiele Orberg reports on a combined analysis of bacteriome, fungome and virome to identify metabolites in patients undergoing allo-SCT. #bmtsm #gvhdsm

X post image

23 Mar 2022

Its Day 5 of EBMT! 💻

The @GvHD hub will be covering:

- OS10 Oral session 10: GVHD I, clinical

#EBMT22

X post image

22 Mar 2022

That’s the end of our coverage for Day 4 of the EBMT 48th Annual Meeting!

EBMT is coming to an end tomorrow, be sure to come back and catch all the final key insights, topics and interviews our medical education hubs will be covering virtually! 💻

#EBMT22

X post image

22 Mar 2022

CONGRESS #EBMT22 | Working party session on current clinical practice in chronic #GvHD: Olaf Penack @ChariteBerlin discusses the difficulties and possible solutions to overcome cGVHD complications. #bmtsm #gvhdsm

X post image

22 Mar 2022

CONGRESS #EBMT22 | Plenary⚡️ @mohty_EBMT provides an overview of post-transplant Cy vs ATG for #GvHD prophylaxis: PTCy comparable to ATG in 10/10 MUD setting. Will combining PTCy with ATG further reduce incidence of GvHD❓ #bmtsm #gvhdsm

X post image

22 Mar 2022

CONGRESS #EBMT22 | @zina_peric also emphasises the role of supportive care alongside systemic therapy for sclerotic chronic #GvHD. #bmtsm #gvhdsm

X post image

22 Mar 2022

CONGRESS #EBMT22 | @zina_peric, University of Zagreb highlights the importance of identifying and treating sclerotic organ manifestations of chronic #GvHD as early as possible, involving multidisciplinary teams. #bmtsm #gvhdsm

X post image

22 Mar 2022

CONGRESS #EBMT22 | Steve Pavletic @theNCI provides an update on the NCI cGvHD conference 2020, highlighting key NIH working-group publications addressing prevention, early diagnosis, pre-emptive therapy, treatment and focus on highly morbid forms #bmtsm #gvhdsm

X post image

22 Mar 2022

CONGRESS #EBMT22 | Bruce Blazar @UMNews provides novel insights into the biology of ocular and CNS chronic #GvHD, and presents data on cGvHD from non-human primates #bmtsm #gvhdsm

X post image

22 Mar 2022

CONGRESS #EBMT22 | Robert Zeiser, Freiburg University Medical Center, on biology-driven approaches to treating acute #GvHD. Multiple cells are involved; novel regenerative approaches such as uhCG/EGF alongside immunosuppression may improve outcomes #bmtsm #gvhdsm

X post image

22 Mar 2022

CONGRESS #EBMT22 | Shernan Holtan @sghmd @UMNews hypothesizes the causes of steroid-refractory acute #GvHD, proposing the involvement of 3Ds: damage, dysbiosis and different cell subsets #bmtsm #gvhdsm

X post image

22 Mar 2022

CONGRESS #EBMT22 | Thomas Luft, University Hospital Heidelberg, reviews the important role of endothelial dysfunction in acute #GvHD, and the EASIX score as a global endothelial marker. #bmtsm #gvhdsm

X post image

21 Mar 2022

That’s the end of our coverage for Day 3 of the EBMT 48th Annual Meeting!

Stick around for more key points, interviews and topics coming tomorrow! 🗣

#EBMT22

X post image

21 Mar 2022

CONGRESS #EBMT22 | @DanielWeisdorf @UMNews describes the novel Minnesota risk score for acute #GvHD that stratifies by organ staging. High-risk patients could be candidates for new treatments, whereas low-risk patients could be candidates for less toxic therapy #bmtsm #gvhdsm

X post image

21 Mar 2022

CONGRESS #EBMT22 | @StephanieLeeMD @fredhutch discusses various risk stratification models for chronic #GvHD. None are ready for clinical use: the hunt for applicable risk stratification systems is still ongoing. #bmtsm #gvhdsm

X post image

21 Mar 2022

CONGRESS #EBMT22 | Francis Ayuk presents data from the MAGIC consortium of 20 international centers set up to together identify & validate biomarkers for GvHD risk assessment #bmtsm #gvhdsm

X post image

21 Mar 2022

CONGRESS #EBMT22 | Q&A with Petr Sedláček, Andrew Gennery & @zina_peric on ECP for #GvHD. #bmtsm #gvhdsm

X post image

21 Mar 2022

CONGRESS #EBMT22 | Hildegard Greinix concludes with contraindications for ECP in #GvHD. #bmtsm #gvhdsm

X post image

21 Mar 2022

CONGRESS #EBMT22 | Hildegard Greinix, Medical University Graz on when to use ECP for #GvHD treatment: better than expected 6m OS for steroid-refractory aGvHD; beneficial for pts with high infection risk; does not increase relapse risk; steroid-sparing in cGvHD #bmtsm #gvhdsm

X post image

21 Mar 2022

CONGRESS #EBMT22 | @zina_peric, University of Zagreb, on future prospects for combining ECP with immunosuppressive agents to treat #GvHD. Data is limited, understanding disease biology is key #bmtsm #gvhdsm

X post image

21 Mar 2022

CONGRESS #EBMT22 | Andrew Gennery @UniofNewcastle on the effect of ECP on thymopoiesis and metabolic pathways in acute pediatric #GvHD. Rapid use allows quicker control of GvHD and thymic recovery #bmtsm #gvhdsm

X post image

21 Mar 2022

CONGRESS #EBMT22 | Q&A with @KrogerNicolaus, José Antonio Pérez Simón & Daniel Wolff on treating chronic #GvHD. #bmtsm #gvhdsm

X post image

21 Mar 2022

CONGRESS #EBMT22 | Daniel Wolff concludes his session by summarising the second-line agents in cGvHD, stating that safety and evidence of efficacy is an important driver for treatment decisions #bmtsm #gvhdsm

X post image

21 Mar 2022

CONGRESS #EBMT22 | Daniel Wolff of University Hospital Regensburg reviews the factors influencing second-line treatment decisions for chronic #GvHD. #bmtsm #gvhdsm

X post image

21 Mar 2022

CONGRESS #EBMT22 | @DrCCutler @DanaFarber summarises trial data on extracorporeal photopheresis to treat chronic #GvHD. Insufficient data to support use frontline, but has a role in the steroid-refractory setting #bmtsm #gvhdsm

X post image

21 Mar 2022

CONGRESS #EBMT22 | José Antonio Pérez Simón @HospitalUVRocio discusses #GvHD pathophysiology and how to prevent chronic GvHD #bmtsm #gvhdsm

X post image

21 Mar 2022

Its Day 3 of EBMT!

The @GvHD hub will be covering:

- HDI1 How Do I... treat chronic GVHD?

- HDI2 How Do I... manage multiple facets of GVHD treatment? A focus on ECP

- E5 Tools for risk stratification of GVHD

#EBMT22

X post image

20 Mar 2022

It’s Day 2 of EBMT!

Keep an eye on our page for more EBMT coverage and key insights over the next few days!

#EBMT22
#congressupdates #medicaleducation #cancerawareness

X post image

19 Mar 2022

CONGRESS #EBMT22 | Why is nutrition an important aspect of #GvHD management? Marek Hanza discusses the impact of symptoms on nutrition and provides recommendations to encourage patients to eat well #bmtsm #gvhdsm

X post image

19 Mar 2022

CONGRESS #EBMT22 | Nurses Group session by @zina_peric, University of Zagreb, on supportive care in #GvHD - a multidisciplinary approach is needed for optimal patient management. #bmtsm #gvhdsm

X post image

19 Mar 2022

CONGRESS #EBMT22 | Jaleel Mohammed, RAHCT, reviews the role of physical therapy and its evaluation for management of patients with post transplant #GvHD. Bespoke exercise programs needed; proposal made for a dedicated HSCT case manager to oversee the pt journey #bmtsm #gvhdsm

X post image

19 Mar 2022

CONGRESS #EBMT22 | Nurses Group session: Rubeta Matin @OUHospitals provides practical tips for managing cutaneous #GvHD. #bmtsm #gvhdsm

X post image

19 Mar 2022

CONGRESS #EBMT22 | Nathaniel Triester provides practical tips for the diagnosis and management of oral GvHD, highlighting the importance of life-long surveillance due to increased risk of oral cancer after transplant #bmtsm #gvhdsm

X post image

19 Mar 2022

CONGRESS #EBMT22 | An informative Nurses Group session by Dimitri Roels on ocular #GvHD. Management includes lubrication, reducing inflammation, and surgery in severe cases #bmtsm #gvhdsm

X post image

16 Mar 2022

3 days to go until the 48th Annual Meeting of the EBMT! Are you ready?

Follow our hub on Twitter on March 19–23 to stay up to date on interviews, key insights, and more!

#congressupdates #medicaleducation #cancerawareness #EBMT22

<span> </span>

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

More about...

EBMT 2022 European Society for Blood and Marrow Transplantation

Newsletter

Subscribe to get the best content delivered to your inbox